Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
Martin RM, Turner EL, Young GJ, Metcalfe C, Walsh EI, Lane JA, Sterne JAC, Noble S, Holding P, Ben-Shlomo Y, Williams NJ, Pashayan N, Bui MN, Albertsen PC, Seibert TM, Zietman AL, Oxley J, Adolfsson J, Mason MD, Davey Smith G, Neal DE, Hamdy FC, Donovan JL; CAP Trial Group. Martin RM, et al. Among authors: zietman al. JAMA. 2024 May 7;331(17):1460-1470. doi: 10.1001/jama.2024.4011. JAMA. 2024. PMID: 38581198 Free PMC article. Clinical Trial.
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Wisdom AJ, Yeap BY, Michalski JM, Horick NK, Zietman AL, Christodouleas JP, Kamran SC, Parikh RR, Vapiwala N, Mihalcik S, Miyamoto DT, Zeng J, Gay HA, Pisansky TM, Mishra MV, Spratt DE, Mendenhall NP, Soffen EM, Bekelman JE, Efstathiou JA. Wisdom AJ, et al. Among authors: zietman al. Int J Radiat Oncol Biol Phys. 2024 Sep 30:S0360-3016(24)03444-8. doi: 10.1016/j.ijrobp.2024.09.043. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39357788
Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial.
Coen JJ, Rodgers JP, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou J, Jani AB, Kucuk O, Souhami L, Pugh SL, Sandler HM, Shipley WU. Coen JJ, et al. Among authors: zietman al. Int J Radiat Oncol Biol Phys. 2024 Aug 13:S0360-3016(24)03230-9. doi: 10.1016/j.ijrobp.2024.08.007. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39147209
Why Basic Science Education Matters in Radiation Oncology.
Wallner PE, Steinberg ML, Burmeister J, Curran WJ Jr, Das P, Davis BJ, Haffty BG, Marples B, Zietman AL. Wallner PE, et al. Among authors: zietman al. Am J Clin Oncol. 2024 Jul 1. doi: 10.1097/COC.0000000000001130. Online ahead of print. Am J Clin Oncol. 2024. PMID: 38948937 No abstract available.
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.
Dahl DM, Karrison TG, Michaelson MD, Pham HT, Wu CL, Swanson GP, Shipley WU, Vuky J, Lee RJ, Zietman AL, Souhami L, Chang BK, Deming RL, Ellerton JA, Sandler HM, Rodgers JP, Feng FY, Efstathiou JA. Dahl DM, et al. Among authors: zietman al. Eur Urol Oncol. 2024 Feb;7(1):83-90. doi: 10.1016/j.euo.2023.05.013. Epub 2023 Jul 11. Eur Urol Oncol. 2024. PMID: 37442672 Clinical Trial.
Gender-Affirming Surgery and Cancer: Considerations for Radiation Oncologists for Pelvic Radiation in Transfeminine Patients.
Smart AC, Liu KX, Domogauer JD, Rodriguez-Russo C, Jones B, Dickstein DR, Mancias JD, Shiloh RY, Wintner A, Zietman AL, Marshall DC, Dyer MA, Russo AL. Smart AC, et al. Among authors: zietman al. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):301-311. doi: 10.1016/j.ijrobp.2023.05.028. Epub 2023 May 24. Int J Radiat Oncol Biol Phys. 2023. PMID: 37230432 Free PMC article. Review.
Impact of a negative confirmatory biopsy on risk of disease progression among men on active surveillance for prostate cancer.
Salari K, Kowitz J, Twum-Ampofo J, Gusev A, O'Shea A, Anderson MA, Harisinghani M, Kuppermann D, Dahl DM, Efstathiou JA, Lee RJ, Blute ML, Zietman AL, Feldman AS. Salari K, et al. Among authors: zietman al. Urol Oncol. 2023 Sep;41(9):387.e9-387.e16. doi: 10.1016/j.urolonc.2023.04.018. Epub 2023 May 17. Urol Oncol. 2023. PMID: 37208229
Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.
Schneider AC, Chandrasekar T, Bowler N, Fogg R, Leong JY, Gusev A, Rodgers LH, McCormick SR, Dahl DM, Efstathiou JA, Blute ML, Zietman AL, Wu CL, Smith MR, Van Allen EM, Feldman AS, Salari K. Schneider AC, et al. Among authors: zietman al. J Urol. 2023 Jun;209(6):1112-1119. doi: 10.1097/JU.0000000000003396. Epub 2023 Mar 9. J Urol. 2023. PMID: 36951811
278 results